Veru (NASDAQ:VERU - Get Free Report) issued its earnings results on Thursday, May 8th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%.
Veru Stock Performance
Shares of NASDAQ VERU traded up $0.00 during midday trading on Thursday, hitting $0.51. The company's stock had a trading volume of 110,243 shares, compared to its average volume of 1,729,376. Veru has a 1-year low of $0.45 and a 1-year high of $1.52. The firm's fifty day moving average price is $0.53 and its 200-day moving average price is $0.63. The firm has a market cap of $74.22 million, a P/E ratio of -1.95 and a beta of -0.74.
Insiders Place Their Bets
In related news, Director Michael L. Rankowitz acquired 95,279 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were purchased at an average price of $0.55 per share, for a total transaction of $52,403.45. Following the purchase, the director now owns 195,279 shares in the company, valued at $107,403.45. This represents a 95.28% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 14.90% of the stock is owned by insiders.
About Veru
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Read More
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
